摘要
目的探讨1.5T MRI中运用氢质子波谱成像(1 H-MRS)技术在脂肪肝疗效中的应用。方法采用自身治疗前后对照的方法,选取15例代谢综合征患者用艾塞那肽(Exenatide)并进行糖尿病饮食,分别于治疗前和治疗后8周各行1次1 H-MRS检查,测得肝内脂肪含量(IHCL);同时测量患者治疗前后体质量(BW)、腰围、体质量指数(BMI)、甘油三脂(TG)。结果结果经对数转换符合正态分布,后进行配对t检验,治疗前IHCL高于治疗8周后的IHCL,差异具有统计学意义(P<0.05);校正了性别、年龄后,以IHCL为因变量,以BMI、腰围、TG为自变量行相关分析,结果显示IHCL和BMI(r=0.489,P<0.05)、腰围(r=0.416,P<0.05)、TG(r=0.347,P<0.05)。结论 1 H--MRS脂肪定量技术可用于临床评估脂肪肝治疗效果,并且是一种无创脂肪定量的新方法。
Objective To investigate the feasibility of proton magnetic resonance spectroscopy （1^H-MRS） imaging, by which to quantitatively analyze liver fat content for therapeutic evaluation of fatty liver at 1.5 T MRI. Methods Using controlled trials, we selected 15 cases of patients with metabolic syndrome who were under treatment of exenatide and dia- betic diet. All of them were examined with proton MRS by Philips Intera Achieva 1.5 T MRI before treatment and 8 weeks after treatment respectively. Intrahepatic lipid content （IHCL） were calculated. The values of the patients： body weight （BW）, body mass index （BMI）, triglycerides, simultaneously were measured before and 8 weeks after treatment. Results Paired t-test was used when results were logarithmically transformed to fit the normal distribution, IHCL values decreased on 8 weeks after treatment [12.1（7.9-21.2） [vs 7.6（5.3-15.6） ], P 〈0. 013. There were positive corre- lation between IHCL and BMI （ r =0.489, P 〈0.05）, waistline （ r =0.416, P 〈0.05）, TG（ r =0.347, P 〈0.05）. Correlation analysis showed that BMI （ r = 0. 489, P 〈0.05）, waist circumference （ r = 0.416, P 〈0.05）, TG（ r = 0.447, P 〈0.05）, TG（ r = 0.347, P 〈0.05） was associated with the IHCL. Conclusion 1^H--MRS fat quantitative techniques can clinically evaluate fatty liver therapeutic effect, and is a new method of noninvasive fat quantitative measure- ment.
出处
《医学影像学杂志》
2014年第9期1623-1626,共4页
Journal of Medical Imaging
关键词
脂肪肝
艾塞那肽
磁共振成像
对比研究
Fatty liver
Exenatide
Hydrogen proton magnetic resonance spectroscopic imaging
Comparative study
